Oxford Immunotec Global PLC (NASDAQ:OXFD) Institutional Investor Sentiment Analysis

June 18, 2018 - By Migdalia James

Oxford Immunotec Global PLC (NASDAQ:OXFD) Logo

Sentiment for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Oxford Immunotec Global PLC (NASDAQ:OXFD) institutional sentiment decreased to 1.34 in 2018 Q1. Its down -0.23, from 1.57 in 2017Q4. The ratio is negative, as 39 institutional investors opened new and increased equity positions, while 29 decreased and sold their stakes in Oxford Immunotec Global PLC. The institutional investors in our partner’s database now own: 23.37 million shares, down from 23.93 million shares in 2017Q4. Also, the number of institutional investors holding Oxford Immunotec Global PLC in their top 10 equity positions was flat from 2 to 2 for the same number . Sold All: 9 Reduced: 20 Increased: 29 New Position: 10.

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for the management of immune-regulated conditions. The company has market cap of $366.61 million. The Company’s development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. It currently has negative earnings. The firm develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

The stock increased 4.15% or $0.56 during the last trading session, reaching $14.16. About 94,980 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 0.28% since June 18, 2017 and is uptrending. It has underperformed by 12.29% the S&P500.

Analysts await Oxford Immunotec Global PLC (NASDAQ:OXFD) to report earnings on August, 7. They expect $-0.24 earnings per share, up 25.00 % or $0.08 from last year’s $-0.32 per share. After $-0.40 actual earnings per share reported by Oxford Immunotec Global PLC for the previous quarter, Wall Street now forecasts -40.00 % EPS growth.

New Leaf Venture Partners L.L.C. holds 5.73% of its portfolio in Oxford Immunotec Global PLC for 852,497 shares. Consonance Capital Management Lp owns 2.34 million shares or 2.66% of their US portfolio. Moreover, First Light Asset Management Llc has 1.71% invested in the company for 626,585 shares. The Vermont-based Birchview Capital Lp has invested 1.45% in the stock. Redmile Group Llc, a California-based fund reported 2.47 million shares.

Since January 1, 0001, it had 0 insider buys, and 2 selling transactions for $74,342 activity.

Oxford Immunotec Global PLC (NASDAQ:OXFD) Ratings Coverage

Ratings analysis reveals 100% of Oxford Immunotec’s analysts are positive. Out of 2 Wall Street analysts rating Oxford Immunotec, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $15.0 while the high is $15.0. The stock’s average target of $15 is 5.93% above today’s ($14.16) share price. OXFD was included in 2 notes of analysts from January 8, 2018. Cowen & Co maintained the shares of OXFD in report on Monday, January 22 with “Buy” rating. The rating was maintained by Piper Jaffray with “Buy” on Monday, January 8.

More notable recent Oxford Immunotec Global PLC (NASDAQ:OXFD) news were published by: Globenewswire.com which released: “Investor Expectations to Drive Momentum within Oxford Immunotec Global, Financial Engines, Brookfield Property …” on June 05, 2018, also Nasdaq.com with their article: “Oxford Immunotec’s T-SPOT®.TB Test Included in the World Health Organization’s First-Ever Essential Diagnostics List” published on May 21, 2018, Globenewswire.com published: “Oxford Immunotec to Present at the Jefferies 2018 Healthcare Conference” on May 29, 2018. More interesting news about Oxford Immunotec Global PLC (NASDAQ:OXFD) were released by: Globenewswire.com and their article: “Oxford Immunotec Announces Launch of the Accutixâ„¢ Brand” published on May 22, 2018 as well as Nasdaq.com‘s news article titled: “Oxford Immunotec Announces Data Presentations for T-SPOT®.CMV Test at the 2018 American Transplant Congress” with publication date: June 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: